Skip to content

AxoGen

US · AXGN #2714 by market cap Listed 1970
55.75 -0.60 -1.06%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Valuation each multiple against its own 5-year range

P/B ratio 6.73 Expensive vs history 71st percentile
5-year average 5.76 · #102 of 126 in Medical Devices
P/E ratio -88.78 Cheap vs history 14th percentile
5-year average -75.38 · forward -990.08
P/S ratio 12.52 Expensive vs history 100th percentile
5-year average 4.08 · forward 9.48 · #121 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
AxoGen (AXGN) 3.33B -88.49 6.71 0.00%
Abbott Laboratories (ABT) 178.39B 38.29 3.50 2.41%
Medtronic (MDT) 127.84B 24.62 2.54 2.85%
Stryker Corp (SYK) 118.01B 33.01 5.03 1.14%
Boston Scientific (BSX) 60.85B 17.71 2.37 0.00%
Edwards Lifesciences (EW) 58.56B 57.54 5.39 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★☆☆☆ Fair value44.93 Economic moatNone UncertaintyHigh

Trading 19.4% above Morningstar's fair value estimate.

Fair value

Axogen Inc earns a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 25% premium over our quantitative fair value estimate of $44.92 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The firm's lack of profitability undermines our estimated fair value. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. For example, the firm's earnings yield of 1.0% ranks in the bottom 40% compared with peers globally. The earnings generated by the company relative to its share price is concerning, which contributes to our view that shares are expensive.

The company's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 16.6%, for example, ranks in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our unfavorable price/fair value ratio.

Economic moat

With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

AxoGen discussion 0 comments

Add a comment